SNF472

Unassigned

New Medicines

Calcific uraemic arteriolopathy (CUA) in ESRD

Information

New molecular entity
Sanifit
Sanifit

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials

Category

IV formulation of myo-inositol hexaphosphate, which selectively inhibits formation & growth of hydroxyapatite crystals. SNF 472 blocks the final pathway of calcification, inhibiting formation and growth of calcium phosphate micro-crystals in soft tissues.
An uncommon condition, affecting 1-4% of the population with end-stage renal failure [3]. CUA in ESRD is a severe form of vascular calcification characterised by painful necrotic skin ulcers and very high mortality. No approved agents are available for therapeutic use (as of mid-2019) [6].
Calcific uraemic arteriolopathy (CUA) in ESRD
Intravenous